# Researchers Identify Key Genetic Regions Controlling Cannabinoid and Terpene Diversity … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/researchers-identify-key-genetic-regions-controlling-cannabinoid-and-terpene-diversity/ > **Published:** 2026-07-31T12:07:27-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:17:41-04:00 > **Clinical Summary:** New research identifies genetic regions controlling cannabinoid and terpene diversity in cannabis—implications for clinical prescribing and product standardization. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchHempCBDTHCIndustryNeurologySafety Why This Matters Identifying genetic regions controlling cannabinoid and terpene composition enables clinicians to better predict and match specific cannabis products to patient conditions, since different cannabinoid profiles produce distinct therapeutic effects. This finding supports personalized cannabis prescribing by providing the biological basis for understanding why patients may respond differently to various strains. As cannabis becomes increasingly integrated into clinical practice, genetic knowledge allows practitioners to move beyond anecdotal strain recommendations toward evidence-based selection of products with consistent, predictable chemical compositions for their patients’ conditions. Clinical Summary Researchers have identified specific genetic regions that control the production of [cannabinoids and terpenes](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) in cannabis plants, with particular focus on CBDA synthase as a key gene influencing THCA, CBDA, and CBGA levels. This pharmacogenetic discovery has direct implications for standardizing cannabis products and predicting their chemical composition, which is critical for clinicians prescribing cannabis therapeutically who need consistent, reproducible dosing. Understanding the genetic basis of cannabinoid variation could enable selective breeding or cultivation of cannabis strains with targeted cannabinoid and terpene profiles tailored to specific patient conditions, such as selecting higher-CBD strains for [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) or anti-inflammatory applications. The research suggests that future cannabis products could be more precisely characterized at the genetic level, potentially improving the quality control and clinical predictability that currently limit cannabis as a pharmaceutical agent. Clinicians should anticipate that genetic profiling of cannabis source material may become standard practice, allowing for more personalized and [evidence-based cannabis](https://cedclinic.com/jama-cannabis-review-physician-analysis/) prescribing based on patients’ individual therapeutic needs. Dr. Caplan’s Take “This genomic work is genuinely interesting from a scientific standpoint, but we’re still at the stage of identifying genetic markers in plant material, not yet understanding what these variations mean clinically for patients. We’ll need to see how this translates into actual therapeutic differences when we study these varied chemotypes in controlled human trials before it changes how we approach [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) in practice.” Clinical Perspective 🧬 Identification of genetic loci controlling cannabinoid and terpene production in cannabis plants represents a significant step toward understanding the biochemical basis of strain variation, which has direct implications for standardization and predictability in clinical use. However, clinicians should recognize that genetic markers for cannabinoid content do not necessarily predict clinical efficacy or safety outcomes in individual patients, as pharmacokinetics, individual [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) variation, and the complex interactions between [cannabinoids and terpenes](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) (“entourage effects”) remain incompletely understood. The current research likely reflects only a subset of cannabis genetic diversity, and findings from controlled agricultural or laboratory studies may not fully translate to the heterogeneous cannabis products available to patients. Despite these limitations, advances in plant genomics could eventually enable more consistent product formulation and labeling, reducing variability in patient outcomes and supporting pharmacokinetic research. Clinicians should view this work as foundational 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Researchers%20Identify%20Key%20Genetic%20Regions%20Controlling%20Cannabinoid%20and%20Terpene%20Diversity%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71854)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71854)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Researchers%20Identify%20Key%20Genetic%20Regions%20Controlling%20Cannabinoid%20and%20Terpene%20Diversity%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71854)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [In the Mix: 37 More Articles — June 22, 2026](https://cedclinic.com/mixed-cannabis-industry-articles-june-22-2026/) - [In the Mix: 36 More Articles — June 15, 2026](https://cedclinic.com/36-cannabis-articles-clinical-relevance-june-15-2026/) - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://themarijuanaherald.com/2026/07/researchers-identify-key-genetic-regions-controlling-cannabinoid-and-terpene-diversity-in-marijuana/amp/](https://themarijuanaherald.com/2026/07/researchers-identify-key-genetic-regions-controlling-cannabinoid-and-terpene-diversity-in-marijuana/amp/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).